- Clinical Trials
- April 2024
- 115 Pages
Global
From €1923EUR$2,000USD£1,650GBP
- Report
- February 2024
- 175 Pages
Global
From €4808EUR$5,000USD£4,124GBP
- Drug Pipelines
- April 2024
- 60 Pages
Global
From €1923EUR$2,000USD£1,650GBP
- Report
- February 2024
- 120 Pages
Asia Pacific
From €4760EUR$4,950USD£4,083GBP
- Report
- April 2023
- 106 Pages
Global
From €2163EUR$2,250USD£1,856GBP
- Report
- April 2023
- 180 Pages
Global
From €7212EUR$7,500USD£6,187GBP
- Report
- September 2022
- 95 Pages
Global
From €3798EUR$3,950USD£3,258GBP
- Report
- January 2022
- 200 Pages
Global
From €7212EUR$7,500USD£6,187GBP
- Report
- January 2022
- 60 Pages
Global
From €3798EUR$3,950USD£3,258GBP
- Report
- February 2021
- 33 Pages
Global
€1267EUR$1,318USD£1,087GBP
- Report
- August 2022
United States
From €1865EUR$1,940USD£1,600GBP
- Report
- August 2022
Global
From €760EUR$790USD£652GBP
- Report
- February 2021
Global
From €2846EUR$2,960USD£2,442GBP
- Report
- December 2022
- 69 Pages
Global
From €3361EUR$3,495USD£2,883GBP
- Clinical Trials
- February 2020
- 104 Pages
Global
From €2404EUR$2,500USD£2,062GBP
- Report
- July 2019
- 26 Pages
Global
From €3841EUR$3,995USD£3,295GBP
- Report
- July 2019
- 83 Pages
Global
From €10572EUR$10,995USD£9,069GBP
- Report
- February 2022
- 106 Pages
Global
From €1923EUR$2,000USD£1,650GBP
- Drug Pipelines
- July 2020
- 251 Pages
Global
From €1923EUR$2,000USD£1,650GBP
- Report
- September 2023
- 90 Pages
Global
From €3500EUR$3,899USD£3,108GBP
Hidradenitis Suppurativa (HS) is a chronic, inflammatory skin condition that affects the sweat glands and hair follicles. It is characterized by recurrent, painful, and inflamed nodules, abscesses, and scarring. Treatment for HS typically involves a combination of topical and systemic medications, including antibiotics, anti-inflammatory drugs, and immunosuppressants.
The HS drug market is a subset of the larger dermatological drug market. It is composed of a variety of medications used to treat HS, including antibiotics, anti-inflammatory drugs, and immunosuppressants. These drugs are used to reduce inflammation, reduce pain, and prevent further progression of the disease.
Some companies in the HS drug market include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. Show Less Read more